Search
Dehydrocholic acid
go.drugbank.com/drugs/DB11622ApprovedDehydrocholic acid is a synthetic bile acid that was prepared from the oxidation of cholic acid with chromic acid [A33022]. It has been used for stimulation of biliary lipid secretion.
Mixtures: PLASIL®ENZIMATICOAmifampridine
go.drugbank.com/drugs/DB11640ApprovedPatients with LEMS develop serum antibodies against presynaptic P/Q-type voltage-gated calcium channels, leading to decreased presynaptic calcium levels and reduced quantal release of acetylcholine, which … Amifampridine phosphate is a more stable salt that serves as an active ingredient of EMA-approved Firdapse, which was previously marketed as Zenas.
Categories: Heterocyclic Compounds, 1-RingSelumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigationalNF-1 is considered rare, with an estimated incidence of 1/3000 individuals. … [A193611] "The novel MEK 1/2 inhibitor, selumetinib, was initially approved solely for the treatment of pediatric patients with Neurofibromatosis type 1 (NF-1) and symptomatic, inoperable plexiform
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesNaldemedine
go.drugbank.com/drugs/DB11691ApprovedInvestigationalIt is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier.
Categories: Heterocyclic Compounds with 4 or More RingsTropisetron
go.drugbank.com/drugs/DB11699ApprovedInvestigationalWithdrawnAs a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingProducts: NAVOBAN 5 MG 1 AMPUL, Navoban 5 mg - KapselnLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). … [L56127] PBC is a rare, chronic autoimmune liver disease characterized by the destruction of small bile ducts, leading to cholestasis and the systemic accumulation of bile acids, which are hypothesized
Synonyms: 3-((((3R,5R)-3-BUTYL-3-ETHYL-7-METHOXY-1,1-DIOXO-5-PHENYL-2,3,4,5-TETRAHYDRO- 1H-1.LAMBDA.6,4-BENZOTHIAZEPIN-8-YL)METHYL)AMINO)PENTANEDIOIC ACID, PENTANEDIOIC ACID, 3-((((3R,5R)-3-BUTYL-3-ETHYL-2,3,4,5-TETRAHYDRO-7-METHOXY-1,1-DIOXIDO-5-PHENYL-1,4-BENZOTHIAZEPIN-8-YL)METHYL)AMINO)-Categories: Cytochrome P-450 CYP3A Inhibitors, Heterocyclic Compounds, 1-RingLasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class … [A187316] Triptans abort migraines via action at several serotonin receptors, including 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors, and activity at the 5-HT<sub>1B</sub> receptor has been specifically
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsProducts: 1 RayvowRifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawnProduct which allowed it to have a status a priority review. … The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid.
Mixtures: RIFETEM 250 MG / 3 ML AMPUL, 1 ADET, RİF 250 MG/3 ML IM ENJEKSİYONLUK ÇÖZELTİ (1 AMPUL)Categories: MATE 1 Inhibitors, P-glycoprotein inhibitorsDanoprevir
go.drugbank.com/drugs/DB11779InvestigationalDanoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP3A InhibitorsFostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigationalFostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. … HIV-1 fills a necessary niche for therapeutic options in patients left with few, if any, viable treatments.
Categories: Human Immunodeficiency Virus Type 1 (HIV-1) gp120-directed Attachment Inhibitors, Cytochrome P-450 Substrates